IP Library Granted Patent US 8,048,428
Granted Patent B2
US 8,048,428 · App. 11/507,298 · Granted Nov 1, 2011

DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof

Assignee: The Scripps Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,048,428
App. No.
11/507,298
Granted
Nov 1, 2011
Kind
B2
Abstract

A DNA composition effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor polypeptide, which can be a full length VEGF receptor protein or an immunogenic fragment thereof. This invention provides DNA compositions that encode VEGF receptor-2 (KDR), VEGF receptor-1 (Flt-1), or Flk-1 (the murine homolog of KDR), as well as methods of using such a DNA composition to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved.

Claims (8)

1. A DNA composition comprising a DNA construct encoding at least one immunogenic fragment of a VEGF receptor capable of eliciting an immune response against vascular endothelial cells, which is expressible in immune cells, and is incorporated in a pharmaceutically acceptable carrier;

wherein the DNA construct is incorporated in an attenuated bacterial vector.

2. The DNA composition of claim 1 wherein the attenuated bacterial vector is selected from attenuated Salmonella typhimurium, Salmonella typhi, Shigella, Bacillus, Lactobacillus, BCG, Escherichia coli, Vibrio cholerae , and Campylobacter.

3. A DNA composition comprising a DNA construct encoding at least one immunogenic fragment of a VEGF receptor capable of eliciting an immune response against vascular endothelial cells, which is expressible in immune cells, and is incorporated in a pharmaceutically acceptable carrier wherein the DNA construct is incorporated in an attenuated bacterial vector, AroA − , dam − Salmonella typhimurium.

4. A DNA composition comprising a DNA construct encoding at least one immunogenic fragment of a VEGF receptor capable of eliciting an immune response against vascular endothelial cells, which is expressible in immune cells, and is incorporated in a pharmaceutically acceptable carrier wherein the composition further comprises a DNA construct encoding an immune effector protein expressible in immune cells.

5. The DNA composition of claim 4 wherein the immune effector protein is a cytokine.

6. The DNA composition of claim 5 wherein the cytokine is CCL21, IL-2, or CD40LT.

7. The DNA composition of claim 1 wherein the immunogenic fragment of a VEGF receptor comprises at least one immunogenic VEGF receptor fragment consisting of about 8 to 10 consecutive amino acid residues of Flk-1 (SEQ ID NO: 6).

Assignments (5)
CONFIRMATORY LICENSE Recorded Jan 29, 2018
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045171/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2006
From: XIANG, RONG
To: SCRIPPS RESEARCH INSTITUTE, THE
Reel/Frame 018639/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2006
From: NIETHAMMER, ANDREAS G.
To: SCRIPPS RESEARCH INSTITUTE, THE
Reel/Frame 018639/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2006
From: REISFELD, RALPH A.
To: SCRIPPS RESEARCH INSTITUTE, THE
Reel/Frame 018659/0749 →
CONFIRMATORY LICENSE Recorded Nov 3, 2006
From: THE SCRIPPS RESEARCH INSTITUTE
To: US GOVERNMENT - SECRETARY FOR THE ARMY
Reel/Frame 018475/0950 →
Continuity (2)
Continuation In Part 10090183 · Mar 2, 2002
Related Publication 20070059323A1 · Mar 15, 2007